May
25,
2023
|
13:59 PM
Europe/Amsterdam
Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting
Not intended for U.S. and UK Media
Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 …
May
23,
2023
|
19:07 PM
Europe/Amsterdam
Bayer issues new senior bonds with a volume of 3 billion euros
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Issuance consisted of three tranches with maturities between 3.25 and 10 years and was substantially oversubscribed
May
17,
2023
|
13:59 PM
Europe/Amsterdam
Kerendia™ (finerenone) granted expanded indication in China for broad range of patients with chronic kidney disease and type 2 diabetes
Not intended for U.S. and UK Media
Chinese National Medical Products Administration granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase …
May
16,
2023
|
13:11 PM
Europe/Amsterdam
Funding advances BBI-355, a potentially best-in-class checkpoint kinase 1 (CHK1) inhibitor, through meaningful clinical data readouts in Phase 1/2 POTENTIATE clinical trial
May
16,
2023
|
08:29 AM
Europe/Amsterdam
Bayer receives U.S. FDA Fast Track Designation for asundexian atrial fibrillation program
Not intended for UK Media
The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries / Asundexian is being evaluated as a potential improved treatment option in …
May
11,
2023
|
07:29 AM
Europe/Amsterdam
Slow start to the year as expected
Bayer Group business performance in the first quarter of 2023:
Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso New Pharmaceuticals products deliver strong growth – …
May
11,
2023
|
07:29 AM
Europe/Amsterdam
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and pre-clinical product progress / Breadth of research reinforces AskBio’s continued commitment to the development …
May
10,
2023
|
12:59 PM
Europe/Amsterdam
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
Not intended for UK Media
Collaboration will leverage Bicycle Therapeutic’s synthetic peptides for the discovery and development of multiple targeted radioconjugates of the company in oncology / Advancing the use of bicycle peptides as a novel targeting approach in …
May
10,
2023
|
09:59 AM
Europe/Amsterdam
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Not intended for U.S. and UK Media
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) / Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related …
May
09,
2023
|
08:59 AM
Europe/Amsterdam
Bayer to present latest research on treatment of vasomotor symptoms in women with breast cancer receiving endocrine adjuvant therapy at ESMO Breast Cancer 2023
Not intended for U.S. and UK Media - Annual Congress of European Society For Medical Oncology Breast Cancer 2023:
Poster presentation from the REALISE study, a real-world evidence analysis evaluating the status of treatment of vasomotor symptoms (VMS) and symptom burden in women taking adjuvant endocrine therapy (AET) after breast cancer, showing a need for new …
May
04,
2023
|
22:15 PM
Europe/Amsterdam
Bayer opens first Co.Lab Life science incubator in Cambridge
Not intended for U.S. and UK Media
Global Bayer Co.Lab network of life science incubators established to accelerate innovation and foster collaborations within vibrant biotech ecosystems / U.S. flagship location opening in Cambridge, MA, encompasses state-of-the-art laboratories and …